Lepu Biopharma Marches Towards First Sales as Costs Mount
Company’s Puyouheng cancer immunotherapy drug was approved for two indications in China, becoming its first commercialized product Key Takeaways: Lepu Biopharma will incur more operational costs as it builds up…
Burning Rock Localizes as Investors Grow Impatient
Cancer testing company reported a widening loss in the first quarter as it spent heavily to build up its localized business model of providing services through partner hospitals Key Takeaways:…
I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat
Cancer drug maker has been in a wide range of market-moving headlines lately, though its stock still trades near an all-time low Key Takeaways: I-Mab was placed on a list…
FAST NEWS: HutchMed Shares Plunge on U.S. Cancer Drug Rejection
The latest: HutchMed (China) Ltd. (HCM.US; 0013.HK) announced late Monday that its Surufatinib drug for the treatment of advanced neuroendocrine tumors was denied approval by the U.S. Food and Drug…
LinkDoc Formally Withdraws Its U.S. IPO. Next Stop, Hong Kong?
Medical big data company has filed with U.S. securities regulator to officially terminate its plan to raise $200 million through a New York listing Key Takeaways: LinkDoc has formally withdrawn…
Cancer Drug Maker BeiGene Takes Action to Mitigate Delisting Risk
Company has changed auditors in a bid to comply with U.S. law and avoid a potential forced delisting from the Nasdaq Key Takeaways: BeiGene has switched auditors for its New…
Hutchmed Roils Markets With Changing of Its Guard, U.S. Delisting Threat
U.S. securities regulator singles out company for potential delisting, a week after Hutchmed announced its CEO will step down after almost 22 years Key Takeaways U.S. securities regulator says Hutchmed…
